NasdaqGS:VIRBiotechs
How Insider Sale and VIR-5500 Milestone at Vir Biotechnology (VIR) Have Changed Its Investment Story
On 1 May 2026, Vir Biotechnology director Vicki L. Sato sold 22,000 shares under a Rule 10b5-1 plan, while the company and Astellas Pharma completed their collaboration agreement and dosed the first patient in a Phase 1 expansion cohort for VIR-5500 in metastatic prostate cancer.
This combination of insider selling and tangible progress in Vir’s oncology pipeline highlights the growing importance of VIR-5500 within its broader development portfolio.
We’ll now examine how progress on VIR-5500...

